The FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) in late 2025, and it launched in the US in early January 2026
Over time, this buildup can contribute to neurological disorders, chronic fatigue, weakened immune function, and organ damage
Complete data show tirzepatide, Lillys dual-action diabetes drug, brings greater A1C reduction, weight loss than semaglutide
Melanocortin Receptor Selectivity Profiles Both Melanotan II and PT-141 interact with the melanocortin receptor family (MC1R through MC5R), a group of five G-protein-coupled receptors (GPCRs) with distinct tissue distributions and signaling roles
Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, et al